All News

Lungs ILD

Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

d Jack Cush, MD

Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adul

Read Article
RheumNow Podcast square

RheumNow Podcast – Pounds of Prevention (3.5.2021)

d Jack Cush, MD

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article
Population study from Southern Norway shows the incidence of giant cell arteritis is not increasing. Over 13yrs, from pop of 300k they identified 206 GCA pts (72%females). Incidence rate of 16.8/100k per year. Mortality was not increased https://t.co/UA16uIuwD1

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - RA and LFTs NAFLD, NASH and Risks with DMARDs and MTX https://t.co/LYV9WycEjz https://t.co/CMGtU4vclY

Links:

Dr. John Cush RheumNow ( View Tweet)
#RA associated interstifial lung dz has incidence of 1-5 per 1,000 PYs and prevalence as high as 67%; risk factors; age, male sex, Dz duration, CCP Abs; w/ age as best predictor of mortality. There is no clear drug interventions that helps RA-ILD https://t.co/zJvWqt0w6L

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Live is a powerful, interactive meeting delivered by researchers, educators, & clinicians. Sign up to attend virtually or in-person today. https://t.co/SvLpwNYh9c

Links:

Dr. John Cush RheumNow ( View Tweet)

Why it's safe to come to RheumNow Live. Lessons learned from restaurants and flying. https://t.co/R0eYO2GiPd https://t.co/E9vPjzUTgb

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease https://t.co/6A4muejeH9 https://t.co/xQbIoEEscv

Links:

Dr. John Cush RheumNow ( View Tweet)
Download available--Difficult RA Defined https://t.co/6WGMEiwiUk

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow podcast now available! Listen on SoundCloud and Apple/Android podcasts. https://t.co/P6kaqZP0PJ https://t.co/BPQ5Ey7d0r

Links:

Dr. John Cush RheumNow ( View Tweet)
"... think what others won’t think; go where others won’t go; do what others won’t do; and be what others want to be." - Phil knight

Dr. John Cush RheumNow ( View Tweet)

News Feature: Baricitinib Therapy in Covid-19 Pneumonia https://t.co/b3tsLcoXay https://t.co/tjqkk1RLFZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Download available--Arthritis Myths https://t.co/2Kxpou4Fbz

Links:

Dr. John Cush RheumNow ( View Tweet)

We have a robust agenda planned for RheumNow Live. Have you registered yet? https://t.co/3zMtzt4t2H https://t.co/iLNj8XEu4X

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Remission Time What to do when not quite in remission https://t.co/BjALXBPVYm https://t.co/HftUANlU1b

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow LIVE VOTE Survey (RHEUMS only): What Kind of Rheumatologist are You? General Rheum? Selective Rheum? Specialized Rheum? please vote in our quick 4Q survey https://t.co/2c5fIgcJ5X https://t.co/LgK8yiXEWC

Links:

Dr. John Cush RheumNow ( View Tweet)
Influenza Numbers are way down this year due to COVID mitigation methods, school/office closings, reduced travel/mobility. As of Jan 31st only 155 hospitalized with the flu (98% less than 2019-2020 flu season - 8,633 people were hospitalized with the flu) https://t.co/6c2YQKbt57?

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Weight Loss to Avert Risk of Gout https://t.co/wzf69PvSJc https://t.co/Dph4OAC2Ar

Links:

Dr. John Cush RheumNow ( View Tweet)
2021 Rheumatollgy drugs lead television advertising spending: #1 Humira ($65.8 million); #6 Xeljanz ($33.9 mill); #7 Skyrizi ($40 mill); #8 Enbrel ($25.8mill); #9 Rinvo ($12+ mill) https://t.co/Pan9Vr5kLt

Links:

Dr. John Cush RheumNow ( View Tweet)

Today the FDA approved tocilizumab (Actemra) for use in Systemic Sclerosis-Associated Interstitial Lung Disease for "Slowing the rate of decline in pulmonary function in adult patients with SSc-ILD" Rec dose is 162 mg SC q week (IV dose not approved) https://t.co/HXTRPiYEfZ

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×